Hengrui Pharma(SH:600276) Zhi Tong Cai Jing·2025-09-29 08:41Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-2129 tablets, aimed at treating acute and chronic pain, with no similar drugs currently approved in the domestic market [1] Group 1: Company Developments - The company's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., and Shanghai Heng Rui Medicine Co., Ltd. have been authorized to conduct clinical trials for HRS-2129 tablets [1] - The total research and development investment for the HRS-2129 project has reached approximately 11.24 million yuan [1] Group 2: Market Context - There are currently no approved drugs targeting the same mechanism as HRS-2129 in the domestic market, indicating a potential competitive advantage for the company [1]